Skip to content
Search AI Powered

Latest Stories

CVS Health halts sale of phenylephrine cold and cough products

The panel of advisors pulled the OTC medicine from the shelves due to its ineffectiveness in unblocking stuffy nose

The American healthcare company, CVS Health, has decided to remove the cold and cough pills containing phenylephrine from the drug stores.


The following decision comes after the health regulator, the US Food and Drug Administration (FDA) determines the decongestant is ineffective towards flu if taken orally.

However, when ingested in pill or tablet form, this ingredient fails to reach its destination from the stomach to the nasal passages.

CVS Health spokesperson told USA Today, "We are removing a small number of oral decongestant products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores but will continue offering many other oral cough and cold products to meet consumer needs.”

They almost run more than 9,000 stores in the US whereas their rival, Walgreens has not yet taken the step to remove over-the-counter medications from their shelves.

iStock 1013348316 Phenylephrine is a common ingredient found in Benadryl, Kenvue's Tylenol, Haleon's Advil, Sudafed, and Dayquil. Credit: iStock

A Walgreens spokeswoman mentioned that the company is closely monitoring the situation and collaborating with its clinical integrity office and suppliers "on appropriate next steps."

Phenylephrine is a common ingredient found in several prominent cough and cold syrups sold in the U.S., including Benadryl, Kenvue's Tylenol, Haleon's Advil, Sudafed, and Dayquil.

This shift occurred primarily after a 2006 law restricted access to pseudoephedrine, a substance that can be used in the production of methamphetamine.

However, Dayquil will continue to be available at CVS stores because it contains a combination of active ingredients.

This ensures that these trusted medications remain accessible to customers.

The experts said some potential benefits of removing the ingredient include "lowering of overall healthcare costs, and avoiding missed opportunities for use of more effective treatments" like going to the doctor.

Dr Alison Cave, chief officer of MHRA commented on the usage of medicines containing phenylephrine, she said: “There have been no new safety concerns identified with phenylephrine-containing products and people can continue to use as directed.

“If you have any concerns about a medicine you are taking, please seek advice from a healthcare professional.”

More For You

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

Chronic inflammation is linked to more than 50 per cent of all deaths worldwide and one in five cancers.

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

When Hemant Patel was struck down by Covid, he was determined to discover what was it that led to the disease having a devastating impact on the lives of people who seemed be healthy – the culmination of his journey is the book, The Complete Anti-Inflammatory Guide.

“I was gasping for breath and counting the number of days I might be alive when I was infected with Covid,” reveals Patel.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less